External analyst notes, journalism, and industry commentary cited with attribution.
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
SAR-bisNTR1's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SAR-bisNTR1. Showing past 6 months and next 12 months · 4 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| SAR-bisNTR1 | Clarity Pharmaceuticals | Radioligand Other | Phase 1[ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | 0 |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
Read-across commentary attached per trial. Phase ordering preserved within each group.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
Phase 4 |
| — |
| — |
| — |
| — |
| — |
| Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | Jiangsu HengRui Medicine Co., Ltd. | — | Phase 3 | — | — | — | — | — |
| 18F-DOPA II - PET Imaging Optimization | University of Alberta | — | Phase 3 | — | — | — | — | — |
| Pancreatic Cancer Diagnosis With FAPI-PET Imaging | Turku University Hospital | — | PHASE2/PHASE3 | — | — | — | — | — |
| Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types | KU Leuven | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | GE Healthcare | — | PHASE2/PHASE3 | — | — | — | — | — |
| NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101 | Leiden University Medical Center | — | Phase 2 | — | — | — | — | — |
| Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) | Institut Curie | — | Phase 2 | — | — | — | — | — |
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Lantheus Medical Imaging | — | PHASE1/PHASE2 | — | — | — | — | — |
| Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Lumicell, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | George Poultsides | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | ITM Oncologics GmbH | — | PHASE1/PHASE2 | — | — | — | — | — |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Blue Earth Diagnostics | — | PHASE1/PHASE2 | — | — | — | — | — |